Lantern Pharma has been granted a patent for a method to treat atypical teratoid/rhabdoid tumor by administering HydroxyUreaMethyl Acylfulvene to subjects with SMARCB1 deletions or alterations. The treatment involves the use of HydroxyUreaMethyl Acylfulvene with negative chirality. GlobalData’s report on Lantern Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Lantern Pharma, Cancer treatment biomarkers was a key innovation area identified from patents. Lantern Pharma's grant share as of January 2024 was 22%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of atypical teratoid/rhabdoid tumor using hydroxyureamethyl acylfulvene
See Also:
A recently granted patent (Publication Number: US11844772B2) outlines a method for treating atypical teratoid/rhabdoid tumors by administering HydroxyUreaMethyl Acylfulvene to subjects with deletions or alterations of the SMARCB1 gene. The treatment involves the use of HydroxyUreaMethyl Acylfulvene with a negative chirality, either alone or in combination with other therapeutic agents like cisplatin or paclitaxel. Additionally, the method includes subjecting the patient to radiation therapy to enhance the treatment's efficacy, with various options such as whole-brain irradiation or radio surgery.
Furthermore, the patent describes a method for determining the sensitivity of a specimen to HydroxyUreaMethyl Acylfulvene by measuring the expression levels of SMARCB1. This method aims to identify patients who are likely to benefit from the treatment based on their genetic profile. The patent also covers the use of HydroxyUreaMethyl Acylfulvene in patients who have previously been treated for prostate cancer and are at risk of cancer recurrence, showcasing the potential of this treatment in a broader oncological context. Overall, the patent provides a comprehensive framework for utilizing HydroxyUreaMethyl Acylfulvene in the treatment of atypical teratoid/rhabdoid tumors, highlighting its potential as a targeted therapy option for patients in need.
To know more about GlobalData’s detailed insights on Lantern Pharma, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
